NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade
In conclusion, NDRG2 serves as an inhibitor of SCLC, and its cancer-inhibiting effects are achieved through the suppression of AKT/mTOR via the activation of PTEN. This work suggests that NDRG2 is a potential druggable target for SCLC treatment.PMID:38537875 | DOI:10.1016/j.taap.2024.116915 (Source: Toxicology and Applied Pharmacology)
Source: Toxicology and Applied Pharmacology - March 27, 2024 Category: Toxicology Authors: Zhenchuan Ma Yuefeng Ma Jie Feng Zhengshui Xu Chuantao Cheng Jie Qin Shaomin Li Jiantao Jiang Ranran Kong Source Type: research
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research
Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer
CONCLUSION: Pretreatment PCT is an independent factor associated with PFS in extensive-stage SCLC patients treated with first-line chemotherapy, but pretreatment NLR reflects no significant prognostic value in our study.PMID:38536706 | PMC:PMC10978019 | DOI:10.1080/15384047.2024.2331273 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - March 27, 2024 Category: Cancer & Oncology Authors: Dongfang Chen Jianlin Xu Yizhuo Zhao Baohui Han Runbo Zhong Source Type: research
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research
Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer
CONCLUSION: Pretreatment PCT is an independent factor associated with PFS in extensive-stage SCLC patients treated with first-line chemotherapy, but pretreatment NLR reflects no significant prognostic value in our study.PMID:38536706 | PMC:PMC10978019 | DOI:10.1080/15384047.2024.2331273 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - March 27, 2024 Category: Cancer & Oncology Authors: Dongfang Chen Jianlin Xu Yizhuo Zhao Baohui Han Runbo Zhong Source Type: research
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research
Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer
CONCLUSION: Pretreatment PCT is an independent factor associated with PFS in extensive-stage SCLC patients treated with first-line chemotherapy, but pretreatment NLR reflects no significant prognostic value in our study.PMID:38536706 | PMC:PMC10978019 | DOI:10.1080/15384047.2024.2331273 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - March 27, 2024 Category: Cancer & Oncology Authors: Dongfang Chen Jianlin Xu Yizhuo Zhao Baohui Han Runbo Zhong Source Type: research
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research
Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer
CONCLUSION: Pretreatment PCT is an independent factor associated with PFS in extensive-stage SCLC patients treated with first-line chemotherapy, but pretreatment NLR reflects no significant prognostic value in our study.PMID:38536706 | PMC:PMC10978019 | DOI:10.1080/15384047.2024.2331273 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - March 27, 2024 Category: Cancer & Oncology Authors: Dongfang Chen Jianlin Xu Yizhuo Zhao Baohui Han Runbo Zhong Source Type: research
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research
